Tango Therapeutics Shares Plunge on Disappointing Quarterly Results

Tango Therapeutics faced significant selling pressure as investors reacted to disappointing second-quarter 2025 financial results. The biotechnology company reported both a dramatic revenue decline and expanding losses, overshadowing clinical development progress across its therapeutic pipeline.

The company’s financial results for Q2 2025 revealed substantial challenges, with revenue collapsing to just $3.2 million. This represents a devastating 84% decrease compared to the same period in 2024, when Tango Therapeutics generated $19.9 million in revenue.

Losses widened considerably, with the company reporting a net loss of $38.9 million ($0.35 per share), significantly higher than the $25.6 million loss recorded during the prior year’s quarter. These figures fell well below analyst expectations, accelerating the stock’s downward trajectory.

Clinical Advancements Amid Financial Challenges

Despite the troubling financial Read more...